UY39779A - MACROCYCLIC COMPOUNDS TO TREAT DISEASES - Google Patents
MACROCYCLIC COMPOUNDS TO TREAT DISEASESInfo
- Publication number
- UY39779A UY39779A UY0001039779A UY39779A UY39779A UY 39779 A UY39779 A UY 39779A UY 0001039779 A UY0001039779 A UY 0001039779A UY 39779 A UY39779 A UY 39779A UY 39779 A UY39779 A UY 39779A
- Authority
- UY
- Uruguay
- Prior art keywords
- treat diseases
- macrocyclic compounds
- macrocyclic
- compounds
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Abstract
La presente descripción se refiere a compuestos macrocíclicos de biarilo, composiciones farmacéuticas que contienen compuestos macrocíclicos y métodos para usar compuestos macrocíclicos para tratar enfermedades, tales como el cáncer.The present disclosure relates to macrocyclic biaryl compounds, pharmaceutical compositions containing macrocyclic compounds, and methods of using macrocyclic compounds to treat diseases, such as cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191630P | 2021-05-21 | 2021-05-21 | |
| US202263340750P | 2022-05-11 | 2022-05-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39779A true UY39779A (en) | 2023-01-31 |
Family
ID=84141799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039779A UY39779A (en) | 2021-05-21 | 2022-05-19 | MACROCYCLIC COMPOUNDS TO TREAT DISEASES |
Country Status (3)
| Country | Link |
|---|---|
| TW (1) | TW202313632A (en) |
| UY (1) | UY39779A (en) |
| WO (1) | WO2022246092A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110013220A (en) * | 2009-07-31 | 2011-02-09 | 다우어드밴스드디스플레이머티리얼 유한회사 | Novel organic electroluminescent compounds and organic electroluminescent device using the same |
| EP3519402A1 (en) * | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| UA126158C2 (en) * | 2017-07-28 | 2022-08-25 | Тьорнінґ Поінт Терапьютикс, Інк. | Macrocyclic compounds and uses thereof |
| JP2022546043A (en) * | 2019-08-29 | 2022-11-02 | ミラティ セラピューティクス， インコーポレイテッド | KRAS G12D inhibitor |
-
2022
- 2022-05-19 WO PCT/US2022/030077 patent/WO2022246092A1/en unknown
- 2022-05-19 UY UY0001039779A patent/UY39779A/en unknown
- 2022-05-20 TW TW111118803A patent/TW202313632A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202313632A (en) | 2023-04-01 |
| WO2022246092A1 (en) | 2022-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20033467A (en) | MACROCYCLIC COMPOUNDS TO TREAT DISEASES | |
| CO2020000633A2 (en) | Macrocyclic compounds and their uses | |
| ECSP19052302A (en) | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | |
| DOP2018000222A (en) | MCL1 MACROCYCLIC INHIBITORS TO TREAT CANCER BACKGROUND | |
| CL2022001671A1 (en) | Sos1 inhibitors | |
| ECSP20069418A (en) | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | |
| UY37272A (en) | PIRIDINES REPLACED WITH HETEROARILO AND METHODS OF USE | |
| CL2018001685A1 (en) | Heterocyclic compounds as immuno modulators. | |
| BR112017010188A2 (en) | phospholipid ether analogues as cancer-targeting drug carriers | |
| UY39574A (en) | MACROCYCLIC COMPOUND USEFUL TO TREAT CANCER AND PHARMACEUTICAL COMPOSITION CONTAINING IT | |
| UY36702A (en) | PIRIDINES REPLACED AND METHODS OF USE | |
| CR20160072A (en) | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE MEK | |
| CL2023000061A1 (en) | Macrocycles and their use | |
| UY37378A (en) | FUSIONED PIRIDAZINONE TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | |
| BR112023000047A2 (en) | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | |
| CO2019010027A2 (en) | Mythriboscines - Mitochondria-based therapeutic compounds that target cancer cells, bacteria, and pathogenic yeast | |
| BR112012023836A2 (en) | tricyclic compounds and pbk inhibitors containing the same | |
| CL2017001275A1 (en) | Linked urea analogs substituted as sirtuin modulators | |
| ECSP22044525A (en) | COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR | |
| CL2021002946A1 (en) | A substituted tetrahydroisoquinoline derivative as a positive allosteric modulator of d1 | |
| CO2022008817A2 (en) | Macrocycles for use in the treatment of diseases | |
| CO2021008117A2 (en) | Imidazopyridazine and imidazopyridine compounds as activin receptor-type kinase-2 inhibitors | |
| UY39779A (en) | MACROCYCLIC COMPOUNDS TO TREAT DISEASES | |
| GT200700020A (en) | DIBENCILAMINE COMPOUNDS AND DERIVATIVES | |
| ECSP22007557A (en) | A SUBSTITUTED TETRAHYDROISOQUINOLINE DERIVATIVE AS A POSITIVE ALLESTERIC MODULATOR OF D1 |